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Abstracts / Urological Science 26 (2015) 288e293 293ultrasound (HIFU) in localized prostate cancer with respect to oncological
and functional outcomes.
Materials and Methods:We enrolled 97, 161, 114 and 120 patients of RRP,
HDRBT, cryoablation and HIFU respectively for localized prostate cancer
from May 2008 to December 2013. PSA biochemical recurrence, salvage
treatment-free rate, metastasis-free rate, and PSA biochemical recurrence-
free survival were collected for oncological outcomes. Functional out-
comes included complications and serial IIEF-5 scores, IPSS and related
QoL scores.
Results: During nearly three years of follow-up, the patients of HDRBT
experienced higher PSA biochemical recurrence rate overall (54.7%), as
well as D'Amico intermediate-risk (34.4%) and high-risk (61.8%) groups,
lower salvage treatment-free rate (46.7%), andmetastasis-free rate (90.7%).
Besides, the patients of RRP demonstrated higher urethral stricture (29.9%)
and urinary incontinence rate (11.3%). The patients of HIFU revealed lower
de novo erectile dysfunction rate at one year (65.6%), higher serial IIEF-5
scores, lower IPSS and related QoL scores.
Conclusion: Among the four treatments, the patients of HDRBT demon-
strated the worst oncological outcomes in D'Amico intermediate and high-
risk groups. Besides, the patients of RRP had more complications rate in
urethral stricture and urinary incontinence. Moreover, the patients of HIFU
experienced better urinary function improvement and more possible
sexual function preservation. In consideration of trifecta, HIFU may pro-
vide equivalent cancer control and better quality of life for patients of
localized prostate cancer.
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Purpose: Robot-assisted radical prostatectomy (RaRP) is viewed as the
main surgical option in patients with localized prostate cancer. Robotic-
assisted Retzius-sparing radical prostatectomy (Retzius-sparing RaRP) is
also in development to achieve the trifecta (cancer free, continence and
potency). For economic consideration, we modiﬁed the methodology us-
ing the same Retzius-sparing approach but with laparoscope.
Materials and Methods: A total of 5 patients underwentRetzius-sparing
LRP from May to Augustof 2015. General characters of patients, peri-
operative parameters, functional and oncologic datas were collected. Pa-
tient position and trocar placement is identical with our conventional LRP.
The steps of whole procedurewere very similar to the method that SK Lim,
et al. (BJU Int 2014; 114: 236e244) had published to describe the process of
Retzius-sparing RaRP. Continence was deﬁned as no need for pad in daily
life.
Results: The average operative time was 213 minutesand the average
amount of blood loss was195 ml. Two patients received bilateral NVBpreserving while the other three patients received unilateral partial pre-
serving. Four patients got immediate continence control at the ﬁrst day
after Foley removal. The other one had post-operative anastomotic leakage
and initial mild stress urine incontinence but got recovery in 2 weeks.
Conclusions: At the very ﬁrst time we show the Retzius-sparing LRP is a
feasible option for localized prostate cancer. It might result in early
continence control in our initial experience and with less economic cost-
than RaRPfor patients. Further long-term prospective studies are needed
to deﬁne the beneﬁts of this method.
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Purpose: Renal cell carcinoma (RCC) accounts for about 3% of all cancer-
related mortalities worldwide and the risk factors for the development of
RCC have not yet been fully elucidated. Mounting proteomic evidence
suggests that inﬂammatory process plays a role in RCC etiology, and
interleukin-10 (IL-10) is an important immunosuppressive cytokine.
However, little is known about the contribution of IL-10 genotypes to RCC.
The study aimed at evaluating the contribution of IL-10 promoter A-1082G
(rs1800896), T-819C (rs3021097), A-592C (rs1800872) genetic poly-
morphisms to the risk of RCC in Taiwan.
Materials and Methods: Associations of the three IL-10 polymorphic ge-
notypes with the risk of RCC were examined among 92 RCC patients and
580 age- and gender-matched cancer-free controls by polymerase chain
reaction-restriction fragment length polymorphism (PCR-RFLP)
methodology.
Results: The pilot results showed that the percentages of TT and TC for IL-
10 T-819C genotypes were signiﬁcantly higher in the RCC patient group
than those in the healthy control group. The CC genotype carriers were of
lower risk for RCC (odds ratio¼ 0.45, 95% conﬁdence interval¼ 0.23-0.72,
p¼ 0.0033). There is no difference in the distribution of A-1082G or A-
592C genotype between the RCC and control groups.
Conclusions: In summary, the CC genotype of IL-10 T-819C genotype may
have a protective effect on RCC risk in Taiwan. Further investigation with
larger sample size in addition to genotype-phenotype correlation and
intracellular mechanisms are our future work.
